The 12th Invest in ME Conference, Part 1
OverTheHills presents the first article in a series of three about the recent 12th Invest In ME international Conference (IIMEC12) in London.
Discuss the article on the Forums.

Nice cg53 review - stakeholder comments.

Discussion in 'Action Alerts and Advocacy' started by Anglia ME Action (UK), Nov 13, 2010.

  1. Anglia ME Action (UK)

    Anglia ME Action (UK)


    NICE is undertaking its scheduled 3-yearly review of its 'CFS/ME' Clinical Guideline 53 during a very short-lived consultation period of 1st to 14th November 2010. The executive view NICE has already declared for its review however is that it sees no reason not to leave CG53 unchanged: by claiming there is no new evidence that warrants rewriting of their original Guideline published in August 2007. See the NICE web addresses below for further details.

    The text of the two respective Stakeholder Responses from the 25% ME Group and the East Anglia ME Patient Partnership (EAME) are now available online at:

    I believe these stakeholder responses utterly demolish any claim NICE has that the core CBT/GET treatments they recommended are genuinely evidence-based. They similarly remove any doubt that it is just patients that believe CG53 is "unfit for purpose" and call for an urgent rewriting of CG53 by a completely different Guideline Development Group.

    Kev Short.

    NICE CG53 Review Addresses:

    [Message ends - please repost widely]
  2. pictureofhealth

    pictureofhealth XMRV - L'Agent du Jour

    Thank you very much for posting these Kevin. Both documents are very clear. Do we have redress in the European courts if nothing changes in the UK, do you happen to know?

See more popular forum discussions.

Share This Page